Atypical and conventional antipsychotic drugs in treatmentnaive first-episode schizophrenia: A 52-week randomized trial of clozapine vs chlorpromazine

Jeffrey A. Lieberman, Michael Phillips, Hongbin Gu, Scott Stroup, Peiyan Zhang, Lan Kong, Zhongfu Ji, Gary Koch, Robert M. Hamer

Research output: Contribution to journalArticle

249 Citations (Scopus)

Abstract

The purported advantages of second-generation or ‘atypical’ antipsychotics relative to first-generation antipsychotics have not been examined in patients with a first episode of schizophrenia. This flexible-dose study examined efficacy and safety in a randomized, doubleblind, 52-weektrial, comparing chlorpromazine (CPZ) and clozapine (CLZ) in treatment naive patients experiencing their first episode of schizophrenia. In all, 160 inpatients with first-episode schizophrenia or schizophreniform disorder were randomized to CPZ or CLZ and followed them for 52 weeks or untildropout. The primary efficacy measure was time to first remission and proportion of time remaining in remission. The analysis was supplemented by comparisons on a profile of clinicalsymptoms and side effects. Of these first-episode patients, 80% achieved remission within 1 year (79% CPZ, 81% CLZ). The Kaplan-Meier estimated median time to first remission was 8 weeks for CLZ vs 12 weeks for CPZ (χ2(l) — 5.56, p — 0.02). Both the rate of first achieving remission and the odds for being in remission during the trialwere almost doubled for the CLZ group in comparison with the CPZ group. At 12 weeks, CLZ was superior on many rating scale measures of symptom severity while CPZ was not superior on any. These symptom differences remained significant when controlling for EPS differences. By 52 weeks many of the symptom differences between groups were no longer significantly different. Generally, CLZ produced fewer side effects than CPZ, particularly extrapyramidalside effects. There was no significant difference between treatments in weight change or glucose metabolism. For each prior year of untreated psychosis, there was a 15% decrease in the odds of achieving remission (OR=0.85; CI 0.75-0.95). A high proportion of first-episode patients remitted within 1 year. We detected no difference in the proportion of first-episode patients receiving CLZ or CPZ that achieved remission. However, firstepisode patients receiving CLZ remitted significantly faster and remained in remission longerthan subjects receiving CPZ. While the CLZ group showed significantly less symptomatology on some measures and fewer side effects at 12 weeks, the two treatment groups seemed to converge by 1 year. Longer duration of untreated psychosis was associated with lower odds of achieving remission.

Original languageEnglish (US)
Pages (from-to)995-1003
Number of pages9
JournalNeuropsychopharmacology
Volume28
Issue number5
DOIs
StatePublished - Jan 1 2003

Fingerprint

Clozapine
Chlorpromazine
Antipsychotic Agents
Schizophrenia
Psychotic Disorders
Inpatients
Therapeutics
Safety
Weights and Measures
Glucose

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Lieberman, Jeffrey A. ; Phillips, Michael ; Gu, Hongbin ; Stroup, Scott ; Zhang, Peiyan ; Kong, Lan ; Ji, Zhongfu ; Koch, Gary ; Hamer, Robert M. / Atypical and conventional antipsychotic drugs in treatmentnaive first-episode schizophrenia : A 52-week randomized trial of clozapine vs chlorpromazine. In: Neuropsychopharmacology. 2003 ; Vol. 28, No. 5. pp. 995-1003.
@article{673f01e427c94d02b1538db1fe3a11f8,
title = "Atypical and conventional antipsychotic drugs in treatmentnaive first-episode schizophrenia: A 52-week randomized trial of clozapine vs chlorpromazine",
abstract = "The purported advantages of second-generation or ‘atypical’ antipsychotics relative to first-generation antipsychotics have not been examined in patients with a first episode of schizophrenia. This flexible-dose study examined efficacy and safety in a randomized, doubleblind, 52-weektrial, comparing chlorpromazine (CPZ) and clozapine (CLZ) in treatment naive patients experiencing their first episode of schizophrenia. In all, 160 inpatients with first-episode schizophrenia or schizophreniform disorder were randomized to CPZ or CLZ and followed them for 52 weeks or untildropout. The primary efficacy measure was time to first remission and proportion of time remaining in remission. The analysis was supplemented by comparisons on a profile of clinicalsymptoms and side effects. Of these first-episode patients, 80{\%} achieved remission within 1 year (79{\%} CPZ, 81{\%} CLZ). The Kaplan-Meier estimated median time to first remission was 8 weeks for CLZ vs 12 weeks for CPZ (χ2(l) — 5.56, p — 0.02). Both the rate of first achieving remission and the odds for being in remission during the trialwere almost doubled for the CLZ group in comparison with the CPZ group. At 12 weeks, CLZ was superior on many rating scale measures of symptom severity while CPZ was not superior on any. These symptom differences remained significant when controlling for EPS differences. By 52 weeks many of the symptom differences between groups were no longer significantly different. Generally, CLZ produced fewer side effects than CPZ, particularly extrapyramidalside effects. There was no significant difference between treatments in weight change or glucose metabolism. For each prior year of untreated psychosis, there was a 15{\%} decrease in the odds of achieving remission (OR=0.85; CI 0.75-0.95). A high proportion of first-episode patients remitted within 1 year. We detected no difference in the proportion of first-episode patients receiving CLZ or CPZ that achieved remission. However, firstepisode patients receiving CLZ remitted significantly faster and remained in remission longerthan subjects receiving CPZ. While the CLZ group showed significantly less symptomatology on some measures and fewer side effects at 12 weeks, the two treatment groups seemed to converge by 1 year. Longer duration of untreated psychosis was associated with lower odds of achieving remission.",
author = "Lieberman, {Jeffrey A.} and Michael Phillips and Hongbin Gu and Scott Stroup and Peiyan Zhang and Lan Kong and Zhongfu Ji and Gary Koch and Hamer, {Robert M.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1038/sj.npp.1300157",
language = "English (US)",
volume = "28",
pages = "995--1003",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "5",

}

Atypical and conventional antipsychotic drugs in treatmentnaive first-episode schizophrenia : A 52-week randomized trial of clozapine vs chlorpromazine. / Lieberman, Jeffrey A.; Phillips, Michael; Gu, Hongbin; Stroup, Scott; Zhang, Peiyan; Kong, Lan; Ji, Zhongfu; Koch, Gary; Hamer, Robert M.

In: Neuropsychopharmacology, Vol. 28, No. 5, 01.01.2003, p. 995-1003.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Atypical and conventional antipsychotic drugs in treatmentnaive first-episode schizophrenia

T2 - A 52-week randomized trial of clozapine vs chlorpromazine

AU - Lieberman, Jeffrey A.

AU - Phillips, Michael

AU - Gu, Hongbin

AU - Stroup, Scott

AU - Zhang, Peiyan

AU - Kong, Lan

AU - Ji, Zhongfu

AU - Koch, Gary

AU - Hamer, Robert M.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The purported advantages of second-generation or ‘atypical’ antipsychotics relative to first-generation antipsychotics have not been examined in patients with a first episode of schizophrenia. This flexible-dose study examined efficacy and safety in a randomized, doubleblind, 52-weektrial, comparing chlorpromazine (CPZ) and clozapine (CLZ) in treatment naive patients experiencing their first episode of schizophrenia. In all, 160 inpatients with first-episode schizophrenia or schizophreniform disorder were randomized to CPZ or CLZ and followed them for 52 weeks or untildropout. The primary efficacy measure was time to first remission and proportion of time remaining in remission. The analysis was supplemented by comparisons on a profile of clinicalsymptoms and side effects. Of these first-episode patients, 80% achieved remission within 1 year (79% CPZ, 81% CLZ). The Kaplan-Meier estimated median time to first remission was 8 weeks for CLZ vs 12 weeks for CPZ (χ2(l) — 5.56, p — 0.02). Both the rate of first achieving remission and the odds for being in remission during the trialwere almost doubled for the CLZ group in comparison with the CPZ group. At 12 weeks, CLZ was superior on many rating scale measures of symptom severity while CPZ was not superior on any. These symptom differences remained significant when controlling for EPS differences. By 52 weeks many of the symptom differences between groups were no longer significantly different. Generally, CLZ produced fewer side effects than CPZ, particularly extrapyramidalside effects. There was no significant difference between treatments in weight change or glucose metabolism. For each prior year of untreated psychosis, there was a 15% decrease in the odds of achieving remission (OR=0.85; CI 0.75-0.95). A high proportion of first-episode patients remitted within 1 year. We detected no difference in the proportion of first-episode patients receiving CLZ or CPZ that achieved remission. However, firstepisode patients receiving CLZ remitted significantly faster and remained in remission longerthan subjects receiving CPZ. While the CLZ group showed significantly less symptomatology on some measures and fewer side effects at 12 weeks, the two treatment groups seemed to converge by 1 year. Longer duration of untreated psychosis was associated with lower odds of achieving remission.

AB - The purported advantages of second-generation or ‘atypical’ antipsychotics relative to first-generation antipsychotics have not been examined in patients with a first episode of schizophrenia. This flexible-dose study examined efficacy and safety in a randomized, doubleblind, 52-weektrial, comparing chlorpromazine (CPZ) and clozapine (CLZ) in treatment naive patients experiencing their first episode of schizophrenia. In all, 160 inpatients with first-episode schizophrenia or schizophreniform disorder were randomized to CPZ or CLZ and followed them for 52 weeks or untildropout. The primary efficacy measure was time to first remission and proportion of time remaining in remission. The analysis was supplemented by comparisons on a profile of clinicalsymptoms and side effects. Of these first-episode patients, 80% achieved remission within 1 year (79% CPZ, 81% CLZ). The Kaplan-Meier estimated median time to first remission was 8 weeks for CLZ vs 12 weeks for CPZ (χ2(l) — 5.56, p — 0.02). Both the rate of first achieving remission and the odds for being in remission during the trialwere almost doubled for the CLZ group in comparison with the CPZ group. At 12 weeks, CLZ was superior on many rating scale measures of symptom severity while CPZ was not superior on any. These symptom differences remained significant when controlling for EPS differences. By 52 weeks many of the symptom differences between groups were no longer significantly different. Generally, CLZ produced fewer side effects than CPZ, particularly extrapyramidalside effects. There was no significant difference between treatments in weight change or glucose metabolism. For each prior year of untreated psychosis, there was a 15% decrease in the odds of achieving remission (OR=0.85; CI 0.75-0.95). A high proportion of first-episode patients remitted within 1 year. We detected no difference in the proportion of first-episode patients receiving CLZ or CPZ that achieved remission. However, firstepisode patients receiving CLZ remitted significantly faster and remained in remission longerthan subjects receiving CPZ. While the CLZ group showed significantly less symptomatology on some measures and fewer side effects at 12 weeks, the two treatment groups seemed to converge by 1 year. Longer duration of untreated psychosis was associated with lower odds of achieving remission.

UR - http://www.scopus.com/inward/record.url?scp=0037712923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037712923&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1300157

DO - 10.1038/sj.npp.1300157

M3 - Article

C2 - 12700715

AN - SCOPUS:0037712923

VL - 28

SP - 995

EP - 1003

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 5

ER -